scholarly journals Radiographically Negative, Asymptomatic, Sentinel Lymph Node Positive Cutaneous T-Cell Lymphoma in a 3-Year-Old Male: A Case Report

2012 ◽  
Vol 2012 ◽  
pp. 1-4
Author(s):  
Jeffrey Carson ◽  
Jiri Bedrnicek ◽  
Shahab Abdessalam
Keyword(s):  
Lymph Node ◽  
T Cell ◽  
Sentinel Lymph Node ◽  
Metastatic Disease ◽  
Cell Lymphoma ◽  
Systemic Disease ◽  
Specific Treatment ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Node Positive

We present a case of a 3-year-old male originally diagnosed with a CD30+ anaplastic cutaneous T-cell lymphoma with no evidence of systemic disease after CT scan, PET scan, and bone marrow aspiration. Sentinel lymph node biopsy (SLNB) was performed as an additional step in the workup and showed microscopic disease. Current management/recommendations for cutaneous T-cell lymphoma do not include SLNB. Medical and surgical management of cutaneous malignancies is dramatically different for local versus advanced disease. Therefore adequate evaluation is necessary to properly stage patients for specific treatment. Such distinction in extent of disease suggests more extensive therapy including locoregional radiation and systemic chemotherapy versus local excision only. Two international case reports have described SLNB in cutaneous T-cell lymphoma with one demonstrating evidence of node positive microscopic disease despite a negative metastatic disease workup. This case is being presented as a novel case in a child with implications including lymphoscintigraphy and SLNB as a routine procedure for evaluation and staging of cutaneous T-cell lymphoma if the patient does not demonstrate evidence of metastatic disease on routine workup.

Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1005-1005 ◽  
Author(s):  
Madeleine Duvic ◽  
Jürgen C. Becker ◽  
Stephane Dalle ◽  
Francisco Vanaclocha ◽  
Maria Grazia Bernengo ◽  
...  
Keyword(s):  
T Cell ◽  
Ct Scan ◽  
Phase Ii ◽  
Cell Lymphoma ◽  
Systemic Disease ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Efficacy And Safety ◽  
Deacetylase Inhibitor ◽  
Skin Responses

Abstract Background: Panobinostat is a histone deacetylase inhibitor that has shown promising results in cutaneous T-cell lymphoma (CTCL). Objectives: An open-label, multicenter, Phase II study is being conducted with a primary objective of establishing the efficacy and safety of the pan-deacetylase inhibitor, panobinostat (LBH589), for patients (pts) with relapsed/refractory CTCL with Stage IB–IVA mycosis fungoides (MF) or Sézary syndrome (SS). Methods: Inclusion criteria include adequate organ function, no clinically significant cardiovascular abnormalities (QTcF ≤ 450 ms, ECOG PS ≤2), failure of ≥2 prior systemic therapies, and no prior HDAC inhibitor treatment. Pts were grouped as having bexarotene therapy (Group [Gr] 1) or bexarotene naïve (Gr 2). Panobinostat was administered at a dose of 20 mg orally on Days 1, 3, 5, weekly, every 28 days until progression or unacceptable toxicity. Response was based on a composite score, including skin assessment with the modified Severity-Weighted Assessment Tool (mSWAT) and systemic disease assessed by CT scan. Results: To date, 95 pts (Gr 1=62; Gr 2=33) have enrolled with median age of 58 yrs [range 25–88]: 58 male, 37 female; 70 MF, 25 SS. Median prior treatment regimens are 4 and 3 for Gr 1 and 2, respectively. Most pts were ≥Stage IIB at study entry (Gr 1=42; Gr 2=26) and received 1–17+ (median=3) treatment cycles of panobinostat. In Gr 1, 11/62 pts have had confirmed skin responses by SWAT, including 2 complete skin responses. Confirmatory CT scans are pending for 2 patients. In Gr 2, 4/33 pts had confirmed skin and CT scan responses. Common AEs (>20%; all grades, regardless of causality) included diarrhea, thrombocytopenia, nausea, pruritus, fatigue, and asthenia, and Grade 3/4 AEs (>2%, regardless of causality) included thrombocytopenia, neutropenia, pruritus, diarrhea, and hypophosphatemia. Of 4,542 ECGs analyzed, 2 pts have had QTcF >480 ms; 4 had QTcF >60 ms increase from baseline. Conclusions: Panobinostat continues to demonstrate encouraging clinical activity with a manageable safety profile in pts with CTCL. Per predefined criteria, Group 2 enrollment to Stage 2 is open. Updated efficacy and safety data will be presented.

Lymph Node Histopathologic Findings in Cutaneous T-Cell Lymphoma: A Prognostic Classification System Based on Morphologic Assessment

1992 ◽  
Vol 97 (1) ◽  
pp. 121-129 ◽  
Author(s):  
Eric C. Vonderheid ◽  
Lawrence W. Diamond ◽  
Sue-Min Lai ◽  
Francis Au ◽  
Michael A. Dellavecchia
Keyword(s):  
Lymph Node ◽  
T Cell ◽  
Classification System ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Histopathologic Findings

CUTANEOUS T-CELL LYMPHOMA WITH LYMPH NODE METASTASIS IN AN ADULT ADDAX (ADDAX NASOMACULATUS)

2017 ◽  
Vol 48 (3) ◽  
pp. 933-936 ◽  
Author(s):  
Zoltan S. Gyimesi ◽  
Roy B. Burns ◽  
Sheryl Coutermarsh-Ott ◽  
Chris A. Schiller ◽  
Rita McManamon
Keyword(s):  
Lymph Node ◽  
T Cell ◽  
Lymph Node Metastasis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Node Metastasis

Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma

Blood ◽  
2001 ◽  
Vol 97 (3) ◽  
pp. 624-630 ◽  
Author(s):  
Julia J. Scarisbrick ◽  
Sean Whittaker ◽  
Alun V. Evans ◽  
Elisabeth A. Fraser-Andrews ◽  
Fiona J. Child ◽  
...  
Keyword(s):  
Lymph Node ◽  
T Cell ◽  
Peripheral Blood ◽  
Cell Lymphoma ◽  
Cell Clone ◽  
Tumor Burden ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
T Cell Clone ◽  
Lymph Node Stage

Abstract Erythrodermic cutaneous T-cell lymphoma (CTCL) includes patients with erythrodermic mycosis fungoides who may or may not exhibit blood involvement and Sézary syndrome and in whom hematological involvement is, by definition, present at diagnosis. These patients were stratified into 5 hematologic stages (H0-H4) by measuring blood tumor burden, and these data were correlated with survival. The study identified 57 patients: 3 had no evidence of hematologic involvement (H0), 8 had a peripheral blood T-cell clone detected by polymerase chain reaction (PCR) analysis of the T-cell receptor gene and less than 5% Sézary cells on peripheral blood smear (H1), and 14 had either a T-cell clone detected by Southern blot analysis or PCR positivity with more than 5% circulating Sézary cells (H2). Twenty-four patients had absolute Sézary counts of more than 1 × 109 cells per liter (H3), and 8 patients had counts in excess of 10 × 109 cells per liter (H4). The disease-specific death rate was higher with increasing hematologic stage, after correcting for age at diagnosis. A univariate analysis of 30 patients with defined lymph node stage found hematologic stage (P = .045) and lymph node stage (P = .013) but not age (P = .136) to be poor prognostic indicators of survival. Multivariate analysis identified only lymph node stage to be prognostically important, although likelihood ratio tests indicated that hematologic stage provides additional information (P = .035). Increasing tumor burden in blood and lymph nodes of patients with erythrodermic CTCL was associated with a worse prognosis.The data imply that a hematologic staging system could complement existing tumor-node-metastasis staging criteria in erythrodermic CTCL.

Cell signaling in cutaneous T‐cell lymphoma microenvironment: promising targets for molecular‐specific treatment

2021 ◽  
Author(s):  
Natalia Rendón‐Serna ◽  
Luis A. Correa‐Londoño ◽  
Margarita M. Velásquez‐Lopera ◽  
Maria Bermudez‐Muñoz
Keyword(s):  
T Cell ◽  
Cell Signaling ◽  
Cell Lymphoma ◽  
Specific Treatment ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma

Lymph node image-guided core-needle biopsy for cutaneous T-cell lymphoma staging

2016 ◽  
Vol 175 (6) ◽  
pp. 1397-1400 ◽  
Author(s):  
M. Battistella ◽  
C. Sallé de Chou ◽  
C. de Bazelaire ◽  
J.M. Cayuela ◽  
E. de Kerviler ◽  
...  
Keyword(s):  
Lymph Node ◽  
T Cell ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Core Needle ◽  
Image Guided

DNA-Cytophotometry of Lymph Node Touch Imprints in Cutaneous T-Cell Lymphoma

1988 ◽  
Vol 90 (4) ◽  
pp. 425-429 ◽  
Author(s):  
Stuart R. Lessin ◽  
Gary L. Grove ◽  
Lawrence W. Diamond ◽  
Francis C. Au ◽  
Peter C. Nowell ◽  
...  
Keyword(s):  
Lymph Node ◽  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Dna Cytophotometry

scholarly journals Cavitating Mesenteric Lymph Node Syndrome and Enteropathy-Associated T Cell Lymphoma as First Manifestation of Celiac Disease

2015 ◽  
Vol 10 (3) ◽  
Author(s):  
Rouslan Kotchetkov ◽  
Vishal Kukreti MD
Keyword(s):  
Celiac Disease ◽  
Lymph Node ◽  
T Cell ◽  
Mesenteric Lymph Node ◽  
Cell Lymphoma ◽  
Systemic Disease ◽  
T Cell Lymphoma ◽  
Mesenteric Lymph ◽  
Increased Risk ◽  
Lymph Node Syndrome

Celiac disease (CD) is a common systemic disease, affecting about 1.0% of the population. Classical presentation includes malabsorption syndrome and deficiencies of macro-/micronutrients. Patients with undiagnosed CD may be referred to hematologists with different hematologic issues, including anemia, thrombocytosis, thrombocytopenia, leukopenia, venous thromboembolism, hyposplenism, and IgA deficiency. CD imposes an increased risk of various lymphomas, especially intestinal T- and B-cell lymphomas. Enteropathy-associated T-cell lymphoma (EATL) is a rare and aggressive disease with poor prognosis and often fatal complications. Here we present a case of EATL associated with cavitating mesenteric lymph node syndrome as a first manifestation of undiagnosed CD.

Sign in / Sign up

Export Citation Format

Share Document